Seborrheic Dermatitis Program
Seborrheic Dermatitis
CommercialMarketed
Key Facts
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals' mission is to commercialize its proprietary, stable hypochlorous acid technology as a safe and effective alternative to traditional antimicrobials and disinfectants. The company has achieved significant commercial traction, with its products approved and sold in over 50 countries, and has built a diversified portfolio spanning prescription wound care, OTC dermatology, and veterinary health. Its strategy focuses on expanding its commercial partnerships, growing its direct OTC e-commerce business, and pursuing new regulatory approvals to leverage its versatile platform across multiple high-value markets.
View full company profileTherapeutic Areas
Other Seborrheic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| Topical Roflumilast Foam 0.3% (ZORYVE) | Arcutis Biotherapeutics | Approved |
| SGT-710 | Sol-Gel Technologies | Phase 2 |